The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Antibiotic resistance—What’s dosing got to do with it?
Abstract
OBJECTIVE: This review seeks to identify original research articles that link antibiotic dosing and the development of antibiotic resistance for different antibiotic classes. Using this data, we seek to apply pharmacodynamic principles to assist clinical practice for suppressing the emergence of resistance. Concepts such as mutant selection window and mutant prevention concentration will be discussed. DATA SOURCES: PubMed, EMBASE, and the Cochrane Controlled Trial Register. STUDY SELECTION: All articles that related antibiotic doses and exposure to the formation of antibiotic resistance were reviewed. DATA SYNTHESIS: The escalation of antibiotic resistance continues worldwide, most prominently in patients in intensive care units. Data are emerging from in vitro and in vivo studies that suggest that inappropriately low antibiotic dosing may be contributing to the increasing rate of antibiotic resistance. Fluoroquinolones have widely been researched and publications on other antibiotic classes are emerging. Developing dosing regimens that adhere to pharmacodynamic principles and maximize antibiotic exposure is essential to reduce the increasing rate of antibiotic resistance. CONCLUSIONS: Antibiotic dosing must aim to address not only the bacteria isolated, but also the most resistant subpopulation in the colony, to prevent the advent of further resistant infections because of the inadvertent selection pressure of current dosing regimens. This may be achieved by maximizing antibiotic exposure by administering the highest recommended dose to the patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Shaw, K. J., Rather, P. N., Hare, R. S., & Miller, G. H. (1993) · Microbiological Reviews · doi:10.1128/mmbr.57.1.138-163.1993 · Cited by 1,196
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
The Pharmacodynamics of β‐Lactams
Turnidge, J. D. (1998) · Clinical Infectious Diseases · doi:10.1086/514622 · Cited by 593
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
Blaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Fink, M. P., Snydman, D. R., Niederman, M. S., Leeper, K. V., Johnson, R. H., Heard, S. O., Wunderink, R. G., Caldwell, J. W., Schentag, J. J., & Siami, G. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.547 · Cited by 461
Evolution and spread of antibiotic resistance
Normark, B. H., & Normark, S. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01026.x · Cited by 440
Drusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426
Zhao, X., & Drlica, K. (2001) · Clinical Infectious Diseases · doi:10.1086/321841 · Cited by 397
Wysocki, M., Delatour, F., Faurisson, F., Rauss, A., Pean, Y., Misset, B., Thomas, F., Timsit, J.-F., Similowski, T., Mentec, H., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2460-2467.2001 · Cited by 385
Kinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
Linezolid resistance in clinical isolates of Staphylococcus aureus
Wilson, P. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg104 · Cited by 289
Roberts, J. A., & Lipman, J. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645080-00001 · Cited by 283
Self-citationDong, Y., Zhao, X., Domagala, J., & Drlica, K. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1756 · Cited by 278
Mouton, J. W., & den Hollander, J. G. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.5.931 · Cited by 275
Aminoglycoside-modifying enzymes
Wright, G. D. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00007-7 · Cited by 241
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16814 · Cited by 238
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316814 · Cited by 236
A Meta-Analysis of Extended-Interval Dosing Versus Multiple Daily Dosing of Aminoglycosides
Bailey, T. C., Little, J. R., Littenberg, B., Reichley, R. M., & Dunagan, W. C. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.786 · Cited by 222
Ali, M. Z., & Goetz, M. B. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.796 · Cited by 220
Bliziotis, I. A., Samonis, G., Vardakas, K. Z., Chrysanthopoulou, S., & Falagas, M. E. (2005) · Clinical Infectious Diseases · doi:10.1086/430912 · Cited by 219
Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., & Zinner, S. H. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1604-1613.2003 · Cited by 215
Tam, V. H., Schilling, A. N., Neshat, S., Poole, K., Melnick, D. A., & Coyle, E. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4920-4927.2005 · Cited by 196
Adaptive Resistance to Aminoglycoside Antibiotics from First-Exposure Down-Regulation
Daikos, G. L., Jackson, G. G., Lolans, V. T., & Livermore, D. M. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/162.2.414 · Cited by 181
Mouton, J. W., & Vinks, A. A. T. M. M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00005 · Cited by 177
Daikos, G. L., Lolans, V. T., & Jackson, G. G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.117 · Cited by 163
Continuous infusion of β-lactam antibiotics in severe infections: a review of its role
Roberts, J. A., Paratz, J., Paratz, E., Krueger, W. A., & Lipman, J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.02.002 · Cited by 150
Self-citationJaruratanasirikul, S., Sriwiriyajan, S., & Punyo, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1337-1339.2005 · Cited by 149
Mouton, J. W., Vinks, A. A. T. M. M., & Punt, N. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.733 · Cited by 142
Olofsson, S. K., Marcusson, L. L., Lindgren, P. K., Hughes, D., & Cars, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl135 · Cited by 139
Roberts, J. A., Boots, R. J., Rickard, C. M., Thomas, P., Quinn, J., Roberts, D. M., Richards, B., & Lipman, J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl478 · Cited by 138
Self-citationLöwdin, E., Odenholt, I., & Cars, O. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2739 · Cited by 126
Angus, B., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., & White, N. J. (2000) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2000.00179.x · Cited by 114
Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates
Gillespie, S. H., Basu, S., Dickens, A. L., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki191 · Cited by 108
Knudsen, J. D., Fuursted, K., Raber, S. R., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1247-1254.2000 · Cited by 106
Larsson, A. J., Walker, K. J., Raddatz, J. K., & Rotschafer, J. C. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.4.589 · Cited by 105
Tam, V. H., Louie, A., Deziel, M. R., Liu, W., Leary, R. H., & Drusano, G. L. (2005) · The Journal of Infectious Diseases · doi:10.1086/430611 · Cited by 104
Firsov, A. A., Smirnova, M. V., Lubenko, I. Y., Vostrov, S. N., Абрамович, П. Ю., & Zinner, S. H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl387 · Cited by 100
Strategies to minimize the development of antibiotic resistance.
Baquero, F., & Negri, M. C. (1997) · PubMed · Cited by 95
Why monitor peak vancomycin concentrations?
Saunders, N. J. S. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92890-8 · Cited by 92
Henderson-Begg, S. K., Livermore, D. M., & Hall, L. M. C. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl064 · Cited by 91
Resistance to Nalidixic Acid: A Misconception Due to Underdosage
Stamey, T. A. (1976) · JAMA · doi:10.1001/jama.236.16.1857 · Cited by 83
Croisier, D., Etienne, M., Bergoin, E., Charles, P., Lequeu, C., Piroth, L., Portier, H., & Chavanet, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1699-1707.2004 · Cited by 80
Fung-Tomc, J. C., Kolek, B., & BONNER, D. P. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.6.1289 · Cited by 71
Roosendaal, R., Bakker‐Woudenberg, I. A. J. M., Raffe, M. V. D. B.-V., Berg, J., & MICHEL, M. F. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963774 · Cited by 70
In Vitro Development of Resistance to Ofloxacin and Doxycycline in Bacillus anthracis Sterne
Choe, C. H., Bouhaouala, S. S., Brook, I., Elliott, T. B., & Knudson, G. B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1766-1766.2000 · Cited by 69
Fantin, B., Farinotti, R., Thabaut, A., & Carbon, C. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.3.563 · Cited by 61
Goss, T. F., Forrest, A., Nix, D. E., Ballow, C. H., Birmingham, M. C., Cumbo, T. J., & Schentag, J. J. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800707 · Cited by 59
The inoculum effect: Fact or artifact?
Craig, W. A., Bhavnani, S. M., & Ambrose, P. G. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.07.006 · Cited by 58
Zhanel, G. G., Mayer, M. L., Laing, N. M., & Adam, H. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01620-05 · Cited by 50
Stamey, T. A. (1976) · JAMA · doi:10.1001/jama.1976.03270170023019 · Cited by 50
Gous, A. G. S., Lipman, J., Scribante, J., Tshukutsoane, S., Hon, H., Pinder, M., Mathivha, R. L., Verhoef, L., & Staß, H. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.04.005 · Cited by 49
Self-citationBa, B. B., Feghali, H., Arpin, C., Saux, M., & Quentin, C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.946-953.2004 · Cited by 49
Lister, P., & Wolter, D. J. (2005) · Clinical Infectious Diseases · doi:10.1086/426190 · Cited by 47
Enterococcus faecalis Resistant to Linezolid: Case Series and Review of the Literature
Burleson, B. S., Ritchie, D. J., Micek, S. T., & Dunne, W. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1225.38086 · Cited by 40
Resistance to Quinolones in Gram-Negative Microorganisms: Mechanisms and Prevention
Baquero, F. (1990) · European Urology · doi:10.1159/000464084 · Cited by 40
Olofsson, S. K., Geli, P., Andersson, D. I., & Cars, O. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5081-5091.2005 · Cited by 37
Knudsen, J. D., Odenholt, I., Erlendsdóttir, H., Gottfreðsson, M., Cars, O., Frimodt‐Møller, N., Espersen, F., Kristinsson, K. G., & Gudmundsson, S. R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2499-2506.2003 · Cited by 35
Thorburn, C. E. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.1.15 · Cited by 33
Dose-Ranging Pharmacokinetic Study of Ciprofloxacin after 200-, 300-, and 400-mg Intravenous Doses
Nix, D. E., Spivey, J. M., Norman, A., et al. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202600101 · Cited by 32
Impact of dosage schedule of antibiotics on the treatment of serious infections
Bakker‐Woudenberg, I. A. J. M., & Roosendaal, R. (1990) · Intensive Care Medicine · doi:10.1007/bf01709706 · Cited by 31
Gugel, J., Pereira, A. D. S., Pignatari, A. C. C., & Gales, A. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00144-06 · Cited by 25
Ross, G. H., Wright, D. H., Hovde, L. B., Peterson, M. L., & Rotschafer, J. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2136-2140.2001 · Cited by 20
Cited by
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
Self-citationPharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
Self-citationSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414
Self-citationDulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C., Shirwadkar, C., Eastwood, G. M., Myburgh, J., Paterson, D. L., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis856 · Cited by 394
Self-citationAugmented Renal Clearance: Implications for Antibacterial Dosing in the Critically Ill
Udy, A. A., Roberts, J. A., Boots, R. J., Paterson, D. L., & Lipman, J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318140-000000000-00000 · Cited by 377
Self-citation
Metadata
- Authors
- Roberts, J. A., Kruger, P., Paterson, D. L., & Lipman, J.
- Venue
- Critical Care Medicine
- Published
- 2008-08
- Volume
- 36
- Issue
- 8
- Pages
- 2433-2440
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2073122282
- Cited by
- 339
- References
- 74
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.